- Home
- CTNM vs CABA Comparison
CTNM vs CABA Comparison
Compare CTNM & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- CABA
- Stock Information
- Founded
- CTNM 2009
- CABA 2017
- Country
- CTNM United States
- CABA United States
- Employees
- CTNM N/A
- CABA N/A
- Industry
- CTNM
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTNM
- CABA Health Care
- Exchange
- CTNM Nasdaq
- CABA Nasdaq
- Market Cap
- CTNM 142.3M
- CABA 157.4M
- IPO Year
- CTNM 2024
- CABA 2019
- Fundamental
- Price
- CTNM $5.77
- CABA $1.66
- Analyst Decision
- CTNM Strong Buy
- CABA Strong Buy
- Analyst Count
- CTNM 4
- CABA 7
- Target Price
- CTNM $22.50
- CABA $14.43
- AVG Volume (30 Days)
- CTNM 366.4K
- CABA 1.8M
- Earning Date
- CTNM 08-12-2025
- CABA 08-07-2025
- Dividend Yield
- CTNM N/A
- CABA N/A
- EPS Growth
- CTNM N/A
- CABA N/A
- EPS
- CTNM N/A
- CABA N/A
- Revenue
- CTNM N/A
- CABA N/A
- Revenue This Year
- CTNM N/A
- CABA N/A
- Revenue Next Year
- CTNM N/A
- CABA N/A
- P/E Ratio
- CTNM N/A
- CABA N/A
- Revenue Growth
- CTNM N/A
- CABA N/A
- 52 Week Low
- CTNM $3.35
- CABA $0.99
- 52 Week High
- CTNM $21.58
- CABA $7.27
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- CABA 48.49
- Support Level
- CTNM N/A
- CABA $1.58
- Resistance Level
- CTNM N/A
- CABA $1.73
- Average True Range (ATR)
- CTNM 0.00
- CABA 0.10
- MACD
- CTNM 0.00
- CABA 0.00
- Stochastic Oscillator
- CTNM 0.00
- CABA 65.71
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.